PATH, the non-profit group working to develop vaccines for developing countries, scored again with an announced collaboration with GSK for a vaccine against Malaria. The second generatin vaccine with combine a single dose vaccine from J&J's Crucell followed by two doses of GSK's RTS,S vaccine. This is known as a 'prime-boost' strategy. See Xconomy.
Previously I've written about PATH's success in developing a meningitis vaccine and its subsequent deployment in African populations with the funding assistance of GAVI. Now PATH is -- dare I say it -- moving down the path to attack malaria.